Location History:
- Localita' Collanza, IT (1987)
- Terme-Siena, IT (2009)
- Siena, IT (1992 - 2011)
- Rapolano Terme (Siena), IT (2019)
- Rapolano Terme, IT (2019 - 2023)
Company Filing History:
14 out of 14 
2 out of 3,580 
1 out of 44 
Years Active: 1987-2023
Title: Innovations and Contributions of Massimo Porro
Introduction
Massimo Porro is a distinguished inventor based in Rapolano Terme, Italy, known for his significant contributions to the field of glycoconjugate vaccines. With a remarkable portfolio of 18 patents, his work focuses on advancing immunological defenses against enteropathogenic bacteria and viral gastrointestinal infections.
Latest Patents
Among his latest innovations, Massimo Porro has developed a glycoconjugate vaccine that includes basic units of a molecular construct with built-in multiple epitopes. This formulation aims to offer a broad-spectrum vaccine for protection against infections caused by enteropathogenic bacteria, including Gram-positive and Gram-negative pathogens. His work also encompasses multivalent glycoconjugate vaccines designed for the protection of both the human population and animals from systemic and intestinal infections. These groundbreaking inventions highlight his dedication to enhancing public health through innovative vaccine technology.
Career Highlights
Massimo has worked with various organizations throughout his career, including his tenure at Biosynth S.r.l. and the American Cyanamid Company. His contributions within these companies have significantly influenced vaccine development and the biotechnology sector.
Collaborations
Collaboration is a key aspect of scientific advancement, and Massimo Porro's work is no exception. He has partnered with esteemed colleagues such as Paolo Costantino and Martti Varra, contributing to the collective knowledge and innovations in the field of glycoconjugate vaccines.
Conclusion
Massimo Porro continues to be a vital figure in the invention and development of vaccines, with a strong emphasis on protecting against prevalent infections. His impressive array of 18 patents exemplifies his commitment to innovation and public health.